Biocon Biologics  /  News  /  Press Releases

PRESS RELEASES

2022

Biocon Biologics Recognized as a Company with Great Managers; Two Managers conferred with individual ‘Great Managers Award 2022’
Dec 22, 2022
Shreehas Tambe Appointed as Managing Director & CEO of Biocon Biologics Limited
Dec 5, 2022
Biocon Biologics Completes Acquisition of Viatris’ Global Biosimilars Business
Nov 29, 2022
Biocon Q2FY23 Revenue at Rs 2,384 Cr, Up 23%; Core EBITDA at Rs 816 Cr, Up 34% Gross R&D Spend at Rs 252 Crore, Up 52%
Nov 15, 2022
Biocon Biologics Features in the Prestigious ASIA IP ELITE List for 2022
Nov 11, 2022
Biocon Ranks at No. 8 in ‘Global Top Employers’ List by the U.S. Science Magazine  
Nov 4, 2022
Biocon Sdn. Bhd. Enters Malaysia Book of Records as the First & the Largest Integrated Insulin Manufacturing Facility
Aug 5, 2022
Biocon Q1FY23 Revenue at Rs 2,217 Cr, Up 23%; Net Profit at Rs 144 Cr, Up 71%; Core EBITDA at Rs 660 Cr Up 25%
Jul 27, 2022
University of Glasgow officially Opens Mazumdar-Shaw Advance Research Centre
Jun 9, 2022
Biocon Biologics and Viatris Launch Abevmy® (bBevacizumab), Their Third Oncology Biosimilar, in Canada
May 19, 2022
Biocon Q4FY22 Revenue at Rs 2,476 Cr, Up 21%; Core EBITDA at Rs 815 Cr, Up 37% ; PBT(before Exceptional Items) at Rs 384 Cr, Up 9%
Apr 28, 2022
Biocon Biologics’ Insugen® Awarded a Three-Year Contract by Ministry of Health, Malaysia
Apr 26, 2022
Biocon Biologics’ Partner Receives Positive EU CHMP Opinion for Biosimilar Human Insulin for IV Infusion
Apr 1, 2022
University of Glasgow Names their Flagship Research Centre After John Shaw and Kiran Mazumdar-Shaw
Mar 29, 2022
Kiran Mazumdar-Shaw Elected as the Fellow of Royal Society of Edinburgh (RSE)
Mar 23, 2022
Biocon Biologics to Acquire Viatris’ Biosimilars Assets for up to USD 3.335 billion in Stock and Cash
Feb 28, 2022
Biocon Q3FY22 Revenue at Rs 2,223 Cr, Up 18%; EBITDA at Rs 537 Cr, Up 25%; Biosimilars Up 28% at Rs 981 Cr; Research Services Up 10% at Rs 641 Cr; Generics Up 7% at Rs 607 Cr
Jan 20, 2022

2021

Biocon Biologics* Partner Viatris Wins U.S. Court Decisions on Sanofi Appeals for Lantus® Device Patents
Dec 30, 2021
Clinical Study for Itolizumab in Lupus Nephritis Initiated in India, Post DCGI Approval
Dec 23, 2021
Biocon Enters Prestigious Dow Jones Sustainability Emerging Markets Index
Dec 1, 2021
Biocon Biologics and Viatris Announce Insulin Glargine (insulin glargine-yfgn) Injection Will Be Offered Through the Walgreens Prescription Savings Club
Nov 19, 2021
Biocon Biologics and Viatris Announce Launch of Interchangeable SEMGLEE® (insulin glargine-yfgn) Injection and Insulin Glargine (insulin glargine-yfgn) Injection
Nov 16, 2021
Biocon Biologics Collaborates with RSSDI to Expand Access to its Insulins for Children with Type 1 Diabetes on World Diabetes Day
Nov 15, 2021
Biocon Biologics and Viatris Announce Prime Therapeutics Prefers First-Ever Interchangeable Insulin Biosimilar Semglee® (insulin glargine-yfgn) Injection and Insulin Glargine (insulin glargine-yfgn) Injection on its National Formularies
Nov 4, 2021
Biocon Q2FY22 Revenue up 10% at Rs 1,945 Cr; EBITDA up 35% at Rs 551 Cr; Net Profit (before exceptional items) up 11% at Rs 188 Cr;
Oct 22, 2021
Biocon Biologics’ First-Ever Interchangeable Biosimilar Insulin Glargine, Co-Developed with Commercial Partner Viatris, Preferred on Express Scripts’ Largest Formulary in US
Oct 21, 2021
Biocon Biologics and Serum Institute Life Sciences Announce Strategic Alliance
Sep 16, 2021
Biocon Biologics and Viatris Inc. Receive Historic Approval for First Interchangeable Biosimilar Semglee® (insulin glargine-yfgn injection) for the Treatment of Diabetes
Jul 29, 2021
Biocon Biologics Partners with Adagio Therapeutics to Advance Antibody for the Prevention and Treatment of COVID-19
Jul 26, 2021
Biocon Q1FY22 Revenue at Rs 1,808 Cr, Up 6%; EBITDA at Rs 437 Cr; Biosimilars Up 10 % at Rs 758 Cr; Research Services Up 41 % at Rs 595 Cr;
Jul 23, 2021
Biocon Q4FY21 Revenue at Rs 2,044 Cr, Up 26%; EBITDA at Rs 641 Cr; Up 68%
Apr 29, 2021
Biocon Biologics’ New Monoclonal Antibodies Manufacturing Facility Wins ISPE’s 2021 Facility of the Year Honorable Mention Award
Apr 28, 2021
Biocon Pharma partners with Libbs Farmaceutica to launch generic formulations in Brazil
Mar 29, 2021
Biocon Biologics Appoints Susheel Umesh as Chief Commercial Officer for Emerging Markets
Mar 2, 2021
Biocon Biologics Promotes Shreehas Tambe to Deputy Chief Executive Officer
Mar 1, 2021
Biocon Biologics and Viatris Inc. Receive CHMP Nod for Abevmy®, a Biosimilar to Avastin® (Bevacizumab)
Mar 1, 2021
Biocon Biologics Joins Hands with IDF in its Mission to Promote Diabetes Care, Prevention and effective Management Worldwide
Feb 16, 2021
Biocon Biologics to offer its Oncology Biosimilars through Cancer Access Partnership in over 30 countries
Feb 4, 2021
Biocon Q3FY21 Revenue at ₹ 1,879 Crore, Up 7%; EBITDA at ₹427 Crore; Net Profit at ₹169 Crore; Biosimilars up 11% at ₹769 Crore; Research Services up 13% at ₹585 Crore; Generics down 3% at ₹561 Crore
Jan 22, 2021
Professor Peter Piot Joins the Board of Biocon Biologics Limited as an Independent Director
Jan 21, 2021
Biocon Biologics Receives Rs 555 Cr (USD 75 Million) Capital Injection from ADQ
Jan 7, 2021

2020

Biocon Biologics signs an MoU with CSSC in Tanzania for Mission 10 cents
Dec 15, 2020
Biocon Biologics Receives USD 150 Million Capital Injection from Goldman Sachs
Nov 7, 2020
Biocon Ranked Among Top 5 Biotech Employers Globally
Oct 30, 2020
Biocon Q2FY21 Revenue at Rs 1,760 Cr, Up 10%; EBITDA at Rs 407 Cr; Net Profit (before exceptional item & discontinuing operations) at Rs 174 Cr; Generics Up 8% at Rs 599 Cr; Biosimilars Up 11% at Rs 676 Cr; Research Services Up 12% at Rs 520 Cr.
Oct 23, 2020
Biocon Foundation Signs MoU with Bangalore Metro to Contribute Towards Building Metro Station in Hebbagodi
Oct 8, 2020
Biocon Biologics to Roll Out ‘Mission 10 cents’ in Philippines; Signs MoU with 2 Municipal Governments & reach52 to enable Affordable Access to Quality Insulins
Sep 30, 2020
Biocon Biologics and Mylan Announce Launch of Semglee™ (insulin glargine injection) in the U.S. to Expand Access for Patients Living with Diabetes
Aug 31, 2020
Tata Capital Growth Fund to Invest ~USD 30 million (Rs 225 Crore) in Biocon Biologics for an Equity Stake of 0.85% Deal Values Biocon Biologics at USD 3.5 Billion.
Jul 31, 2020
Biocon Q1FY21 Revenue at Rs 1,690 Cr, Up 14%; EBITDA at Rs 432 Cr; Net Profit (from continuing ops) at Rs 153 Cr Generics up 16% at Rs 599 Cr, Biosimilars up 19% at Rs 692 Cr
Jul 23, 2020
Biocon Biologics and Voluntis Join Hands for Global Collaboration on Digital Therapeutics for Insulins
Jul 21, 2020
Biocon Presented Insights into Clinical Study That Enabled DCGI Approval of Itolizumab for COVID-19
Jul 13, 2020
Biocon’s Breakthrough Drug Itolizumab Receives DCGI Nod for Emergency Use in Moderate to Severe COVID-19 Patients
Jul 11, 2020
Biocon and Mylan Announce U.S. FDA Approval of Semglee™ (insulin glargine injection)
Jun 12, 2020
Kiran Mazumdar-Shaw Wins EY World Entrepreneur of the Year™ 2020 Award
Jun 5, 2020
Biocon’s* Partner Mylan Receives Favourable Ruling from U.S. PTAB on Sanofi’s Four Device Patents for Lantus® SoloSTAR®
Jun 1, 2020
Biocon Biologics Receives DCGI Approval for Emergency Use of CytoSorb® to Treat Critical COVID-19 Patients
May 27, 2020
Biocon Biologics Receives EU GMP Certification for Multiple Biosimilars Manufacturing Facilities in Bengaluru; Expands its Manufacturing Capacity
May 19, 2020
Biocon Earnings Q4FY20 Revenue Up 6% at Rs 1,644 Cr; EBITDA Down 11% at Rs 382 Cr; Net Profit Down 42% at Rs 123 Cr
May 14, 2020
Biocon and Mylan Launch Fulphila®, Biosimilar Pegfilgrastim, in Canada
Apr 28, 2020
Kiran Mazumdar-Shaw Recognized among World’s Top 20 Inspirational Leaders in Biopharmaceuticals in The Medicine Maker ‘Power List 2020’
Apr 27, 2020
Biocon and Mylan Launch Fulphila®, Biosimilar Pegfilgrastim, in Australia
Apr 14, 2020
Biocon & Biocon Biologics Ensuring Manufacturing of Life-Saving Medicines for Patients, Partners and Customers
Mar 27, 2020
Biocon & Mylan Win Patent Litigation Asserted by Sanofi for Insulin Glargine Device Patent in U.S.
Mar 11, 2020
U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon’s Proposed Biosimilar Bevacizumab for Review
Mar 9, 2020
Kiran Mazumdar-Shaw Named EY Entrepreneur of the Year India 2019
Feb 20, 2020
Biocon Q3FY20 Earnings Revenue at Rs 1,784 Cr, Up 14%; EBITDA at Rs 480 Cr, Up 18%; Net Profit (before exceptional item) at Rs 225 Cr, Up 6%
Jan 23, 2020
Kiran Mazumdar-Shaw Honoured with Order of Australia, Australia’s Highest Civilian Honour
Jan 18, 2020
True North to Invest Rs 536.25 Crore in Biocon Biologics for 2.44% Stake
Jan 6, 2020
Biocon Biologics Appoints M.B. Chinappa as Chief Financial Officer
Jan 6, 2020

2019

Biocon Biologics Symposium on ‘100 years of Insulin – Delivering on Universal Access & Equitable Care’ Resonates Well with Leading KOLs at IDF Congress 2019
Dec 11, 2019
Biocon Biologics Takes Forward Its Mission to Unlock Universal Access to Insulins Globally
Dec 3, 2019
Biocon and Mylan Launch Trastuzumab Biosimilar, Ogivri™ (trastuzumab-dkst), in the U.S.
Dec 2, 2019
USFDA Approves Biocon’s sBLA for Pegfilgrastim New Manufacturing Facility
Nov 27, 2019
Kiran Mazumdar-Shaw Conferred with Lifetime Achievement Award by Indian Council of Medical Research
Nov 18, 2019
Biocon Features in the Prestigious ASIA IP ELITE List for the Fourth Consecutive Year
Nov 12, 2019
Biocon’s Biologics Drug Products Facility in Bengaluru Receives EIR from U.S. FDA
Nov 5, 2019
Biocon Moves Up to Rank No. 6 on Science Careers’ Top 20 Global Pharma & Biotech Employers List 2019
Oct 28, 2019
Biocon Q2FY20 Earnings Revenue at Rs 1,611 Cr, Up 17 %; EBITDA at Rs 441 Cr, Up 12%; Net Profit (excluding exceptional item) at Rs 189 Cr, Up 3%
Oct 23, 2019
Biocon Biologics & Just – Evotec Biologics Sign Licensing Deal for a Biosimilar Asset
Oct 10, 2019
Biocon and Mylan Launch First Insulin Glargine Biosimilar, Semglee®, in Australia
Oct 3, 2019
Kiran Mazumdar-Shaw Promises to Enable Universal Access to rh-Insulin by Reducing Prices to Less than 10 US cents /Day for LMICs
Sep 26, 2019
Biocon Biologics Expands its R&D Footprint Through Acquisition
Sep 24, 2019
Biocon’s Malaysia Insulin Glargine Manufacturing Facility Receives EU GMP Certification, Provides Fillip to its Capacity
Aug 22, 2019
Mylan and Biocon Launch First Trastuzumab Biosimilar, Ogivri™, in Australia
Aug 1, 2019
Biocon Q1FY20 Revenue Rs 1,490 Cr, Up 25%; EBITDA Up 51% at Rs 462 Cr; Net Profit (excluding exceptional item) Up 86% at Rs 223 Cr
Jul 25, 2019
Health Canada Approves Biocon and Mylan’s Ogivri™, the First Trastuzumab Biosimilar, for the Treatment of HER2-Positive Breast and Gastric Cancers
May 22, 2019
Biocon and Mylan to Present Final Overall Survival Data for OgivriTM(trastuzumab-dkst), a biosimilar to Herceptin®, at the American Society of Clinical Oncology (ASCO) Annual Meeting
May 16, 2019
Biocon Q4FY19 Revenue Rs 1,557 Cr, Up 26%; EBITDA Up 43% at Rs 431 Cr; Net Profit Up 64% at Rs 214 Cr FY19 Revenue Up 31% at Rs 5,659 Cr; Net Profit Up 143% at Rs 905 Cr
Apr 25, 2019
Kiran Mazumdar-Shaw Conferred With Honorary Doctorate from Deakin University, Australia
Mar 13, 2019
Biocon Appoints Dr. Christiane Hamacher as CEO Of Biocon Biologics India Limited
Mar 1, 2019
Kiran Mazumdar-Shaw elected as Member of the National Academy of Engineering, U.S.
Feb 8, 2019
Biocon Q3FY19 Earnings Revenue at Rs 1,566 Cr, Up 43%; Net Profit at Rs 217 Cr, Up 136% EBITDA at Rs 406 Cr, Up 59%
Jan 24, 2019
Report adverse event/ side effects and/or product complaints for Biocon Biologics products.

* Cookie Notice | Privacy Policy | Terms of Use © 2023, Biocon Biologics Limited (a Subsidiary of Biocon Limited). All Rights Reserved
Share